Contribution of KRAS mutations and c.2369C > T (p.T790M) EGFR to acquired resistance to EGFR-TKIs in EGFR mutant NSCLC: a study on circulating tumor DNA

INTRODUCTION: KRAS oncogene mutations ((MUT)KRAS) drive resistance to EGFR inhibition by providing alternative signaling as demonstrated in colo-rectal cancer. In non-small cell lung cancer (NSCLC), the efficacy of treatment with EGFR tyrosine kinase inhibitors (EGFR-TKIs) depends on activating EGFR...

Descripción completa

Detalles Bibliográficos
Autores principales: Del Re, Marzia, Tiseo, Marcello, Bordi, Paola, D'Incecco, Armida, Camerini, Andrea, Petrini, Iacopo, Lucchesi, Maurizio, Inno, Alessandro, Spada, Daniele, Vasile, Enrico, Citi, Valentina, Malpeli, Giorgio, Testa, Enrica, Gori, Stefania, Falcone, Alfredo, Amoroso, Domenico, Chella, Antonio, Cappuzzo, Federico, Ardizzoni, Andrea, Scarpa, Aldo, Danesi, Romano
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5355124/
https://www.ncbi.nlm.nih.gov/pubmed/26799287
http://dx.doi.org/10.18632/oncotarget.6957

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5355124/
https://www.ncbi.nlm.nih.gov/pubmed/26799287
http://dx.doi.org/10.18632/oncotarget.6957

Ejemplares similares